Roffman Miller Associates Inc. PA Lowers Position in Pfizer Inc. (NYSE:PFE)

Roffman Miller Associates Inc. PA cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 24,056 shares of the biopharmaceutical company’s stock after selling 1,516 shares during the period. Roffman Miller Associates Inc. PA’s holdings in Pfizer were worth $696,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Nomura Asset Management Co. Ltd. lifted its position in Pfizer by 5.6% during the third quarter. Nomura Asset Management Co. Ltd. now owns 1,749,702 shares of the biopharmaceutical company’s stock valued at $50,636,000 after purchasing an additional 92,596 shares in the last quarter. Raab & Moskowitz Asset Management LLC lifted its position in Pfizer by 8.5% during the third quarter. Raab & Moskowitz Asset Management LLC now owns 259,134 shares of the biopharmaceutical company’s stock valued at $7,499,000 after purchasing an additional 20,197 shares in the last quarter. MML Investors Services LLC lifted its position in shares of Pfizer by 4.0% in the third quarter. MML Investors Services LLC now owns 1,387,138 shares of the biopharmaceutical company’s stock valued at $40,144,000 after acquiring an additional 53,486 shares in the last quarter. Laraway Financial Advisors Inc lifted its position in shares of Pfizer by 14.3% in the third quarter. Laraway Financial Advisors Inc now owns 9,262 shares of the biopharmaceutical company’s stock valued at $268,000 after acquiring an additional 1,159 shares in the last quarter. Finally, Headinvest LLC lifted its position in shares of Pfizer by 2.6% in the third quarter. Headinvest LLC now owns 27,439 shares of the biopharmaceutical company’s stock valued at $794,000 after acquiring an additional 698 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Up 0.1 %

Shares of NYSE PFE opened at $25.73 on Monday. The business’s 50 day moving average is $27.47 and its two-hundred day moving average is $28.38. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The stock has a market capitalization of $145.81 billion, a P/E ratio of 34.77, a PEG ratio of 0.70 and a beta of 0.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.17) earnings per share. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, December 2nd. Stockholders of record on Friday, November 8th were paid a dividend of $0.42 per share. The ex-dividend date was Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.53%. Pfizer’s dividend payout ratio is 227.03%.

Analyst Ratings Changes

Several brokerages have recently commented on PFE. Sanford C. Bernstein began coverage on Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective on the stock. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Wolfe Research initiated coverage on Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. Finally, Citigroup initiated coverage on Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average price target of $32.92.

Insider Activity

In other news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.